The HPA axis in major depression: classical theories and new developments

Trends in Neurosciences

Volumn 31, Issue 9, 2008, Pages 464-468

  Pariante, Carmine M ^a   Lightman, Stafford L ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARBON DIOXIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MIFEPRISTONE; PREDNISOLONE; SEROTONIN; TUMOR NECROSIS FACTOR; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1B RECEPTOR;

ADRENAL CORTEX; COGNITIVE DEFECT; CYTOKINE PRODUCTION; FEEDBACK SYSTEM; HORMONAL REGULATION; HORMONE RESISTANCE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIFE EVENT; MAJOR DEPRESSION; MATERNAL DEPRIVATION; MENTAL PATIENT; NERVOUS SYSTEM INFLAMMATION; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOTRAUMA; REVIEW; STRESS; SYMPATHETIC TONE;

DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID;

EID: 50549092885     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2008.06.006     Document Type: Review

References (38)

1. Herbert J., et al. Do corticosteroids damage the brain?. J. Neuroendocrinol. 18 (2006) 393-411
2. Nemeroff C.B., and Vale W.W. The neurobiology of depression: inroads to treatment and new drug discovery. J. Clin. Psychiatry 66 Suppl. 7 (2005) 5-13
3. Pariante C.M. The glucocorticoid receptor: part of the solution or part of the problem?. J. Psychopharmacol. 20 (2006) 79-84
4. Sanchez M.M., et al. Early adverse experience as a developmental risk factor for later psychopathology: evidence from rodent and primate models. Dev. Psychopathol. 13 (2001) 419-449
5. Heim C., and Nemeroff C.B. Neurobiology of early life stress: clinical studies. Semin. Clin. Neuropsychiatry 7 (2002) 147-159
6. Heim C., et al. The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol. Psychiatry 63 (2008) 398-405
7. Weaver I.C., et al. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3480-3485
8. Korosi A., and Baram T.Z. The central corticotropin releasing factor system during development and adulthood. Eur. J. Pharmacol. 583 (2008) 204-214
9. Gardner K.L., et al. Early life experience alters behavior during social defeat: focus on serotonergic systems. Neuroscience 136 (2005) 181-191
10. Gardner, K.L. et al. (2006) Early life experience programs gene expression in serotonin neurons. Program no. 562.15. In 2006 Abstracts Viewer/Itinerary Planner [CD ROM]. Washington, DC: Society for Neuroscience
11. Raison C.L., et al. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006) 24-31
12. O'Brien S.M., et al. Antidepressant therapy and C-reactive protein levels. Br. J. Psychiatry 188 (2006) 449-452
13. Danese A., et al. Childhood maltreatment predicts adult inflammation in a life-course study. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1319-1324
14. Pace T.W., et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 163 (2006) 1630-1633
15. Caspi A., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
16. Bradley R.G., et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch. Gen. Psychiatry 65 (2008) 190-200
17. Nemeroff C.B., et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14293-14296
18. Chourbaji S., et al. Mice that under- or overexpress glucocorticoid receptors as models for depression or posttraumatic stress disorder. Prog. Brain Res. 167 (2008) 65-77
19. Miller A.H., and Raison C.L. Cytokines, p38 MAP kinase and the pathophysiology of depression. Neuropsychopharmacology 31 (2006) 2089-2090
20. Binder E.B., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 36 (2004) 1319-1325
21. van Rossum E.F., et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry 59 (2006) 681-688
22. Carvalho, L.A. et al. Clomipramine in vitro reduces glucocorticoid receptor function in healthy subjects but not depressed patients. Neuropsychopharmacology (in press)
23. Uhr M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57 (2008) 203-209
24. Karst H., et al. Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19204-19207
25. Atkinson H.C., et al. Corticosteroids mediate fast feedback of the rat hypothalamic-pituitary-adrenal axis via the mineralocorticoid receptor. Am. J. Physiol. Endocrinol. Metab. 294 (2008) E1011-E1022
26. Young A.H., et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29 (2004) 1538-1545
27. Lightman S.L., et al. The significance of glucocorticoid pulsatility. Eur. J. Pharmacol. 583 (2008) 255-262
28. Conway-Campbell B.L., et al. Proteasome-dependent down-regulation of activated nuclear hippocampal glucocorticoid receptors determines dynamic responses to corticosterone. Endocrinology 148 (2007) 5470-5477
29. Young E.A., et al. Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry 60 (2003) 24-28
30. Juruena M.F., et al. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl) 189 (2006) 225-235
31. Bhagwagar Z., et al. Increase in concentration of waking salivary cortisol in recovered patients with depression. Am. J. Psychiatry 160 (2003) 1890-1891
32. Bhagwagar Z., et al. Increased salivary cortisol after waking in depression. Psychopharmacology (Berl.) 182 (2005) 54-57
33. 2. Psychoneuroendocrinology 31 (2006) 736-747
34. Spiga F., et al. Effect of the glucocorticoid receptor antagonist Org 34850 on basal and stress-induced corticosterone secretion. J. Neuroendocrinol. 19 (2007) 891-900
35. John S., et al. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol. Cell 29 (2008) 611-624
36. 1 receptor antagonists for the treatment of depression and anxiety. Exp. Clin. Psychopharmacol. 15 (2007) 519-528
37. Griebel G., et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6370-6375
38. Flores B.H., et al. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31 (2006) 628-636